Home › Funds › Stonepine Capital Management, LLC › XERS

Stonepine Capital Management, LLC position in XERS

XERIS BIOPHARMA HOLDINGS INC · Health Care

Stonepine Capital Management, LLC reported holding 280,000 shares of XERS (XERIS BIOPHARMA HOLDINGS INC) in its Q2 2026 13F filing — a position valued at US$2.1M, representing 1.39% of its reported portfolio and ranking #24 among its reported holdings. Stonepine Capital Management, LLC has disclosed XERS holdings in 8 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)280.00K sh
Reported value held$2.10M
Portfolio Weight1.39%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Stonepine Capital Management, LLC's XERS position evolved

Stonepine Capital Management, LLC first disclosed a stake in XERS in Q3 2023 at 5,915,372 shares (US$11.0M). The position peaked in Q4 2023 at 5,937,000 shares, worth US$14.0M. Across 8 filings, Stonepine Capital Management, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 280,000 shares valued at US$2.1M — an increase of 239,970 shares quarter over quarter.. Notable position changes include a 90% trim in Q1 2024 (shares rose 2% over the following quarter), a 101% increase in Q2 2025 (shares rose 74% over the following quarter), a 599% increase in Q2 2026 (shares rose 21% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.92M $11.00M New
Q4 2023 5.94M $13.95M Hold
Q1 2024 598.09K $1.32M Reduce
Q4 2024 182.32K $618.05K New
Q1 2025 102.27K $561.43K Reduce
Q2 2025 205.10K $957.82K Add
Q1 2026 40.03K $232.17K New
Q2 2026 280.00K $2.10M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XERS and 13F data

XERS (XERIS BIOPHARMA HOLDINGS INC) is a Health Care company. 53 other funds we track also report a position in XERS — the largest reported positions include CAPSTONE INVESTMENT ADVISORS, LLC (US$62.6M), Polar Asset Management Partners Inc. (US$28.8M), Rosalind Advisors, Inc. (US$23.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XERS

All XERS fund holders →

FAQ

How long has Stonepine Capital Management, LLC held XERS?

Stonepine Capital Management, LLC has disclosed XERS holdings in 8 of the last 12 reported quarters, going back to Q3 2023.

What is Stonepine Capital Management, LLC's current position in XERS?

As of Q2 2026, Stonepine Capital Management, LLC holds 280.00K shares of XERS (XERIS BIOPHARMA HOLDINGS INC), valued at $2.10M, representing 1.39% of its reported portfolio and ranking #24.

Has Stonepine Capital Management, LLC been buying or selling XERS?

In the latest 13F filing (Q2 2026), Stonepine Capital Management, LLC increased its position in XERS. The position peaked in Q4 2023 at 5.94M shares.

Which other funds hold XERS?

Other major institutional holders of XERS include CAPSTONE INVESTMENT ADVISORS, LLC, Polar Asset Management Partners Inc., Rosalind Advisors, Inc., among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.